Sanofi Appoints Archana Subramanya as Head of R&D India Hub

Regulatory capability building in India just gained a senior architect: Sanofi has appointed Archana Subramanya as Head of its R&D India Hub, signaling a continued push by multinational pharma to embed substantive regulatory and scientific leadership within emerging-market operations rather than treating them as back-office extensions.

Subramanya brings direct precedent to the role. At GSK, she served as Head of Global Regulatory Centers, where she led and expanded capability centres across India, Poland, Egypt, and Mexico. That portfolio spans four distinct regulatory environments, giving her operational fluency in multi-jurisdictional GMP compliance, submission strategy, and the ICH framework as it applies across markets with varying inspection maturity.

For regulatory affairs leads tracking talent flows, the appointment reflects a structural shift that has been building across the sector. Global pharma companies are no longer staffing India hubs primarily for cost arbitrage; they are placing experienced regulatory executives there to anchor regional strategy, support 21 CFR Part 211 and EU GMP-aligned documentation, and build durable pipelines of regulatory science capability. Sanofi's move follows a pattern visible at several multinationals that have elevated their India hub leadership from operational managers to globally credentialed directors.

The R&D India Hub designation itself carries weight. Distinct from a shared-services centre, an R&D hub implies involvement in process validation support, regulatory submission development, and potentially pharmacovigilance or clinical data operations, functions that require alignment with ICH Q10 pharmaceutical quality system principles and direct interface with global regulatory bodies including CDSCO, FDA, and EMA.

Subramanya's appointment will be measured against the hub's output: submission volume, inspection readiness, and the depth of regulatory talent it develops over the next planning cycle.

Source: Media4Growth via Indian Pharma Post, 6 August 2026.